ArticleCurrent medical science2026
MRPL42 Knockdown Suppresses the Malignant Functions of Hepatocellular Carcinoma by Regulating Oxidative Phosphorylation.
Article in Current medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe diagnosis and treatment of hepatocellular carcinoma (HCC) remain unsatisfactory, underscoring the urgent need to explore new regulatory factors. This study aimed to uncover the regulatory role of mitochondrial ribosomal protein L42 (MRPL42) in HCC development and assess its clinical potential as a therapeutic target and prognostic biomarker.
methodsMRPL42 expression in HCC was analyzed in datasets obtained from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. MRPL42 expression was detected via reverse transcription quantitative polymerase chain reaction and immunohistochemistry, and its diagnostic and prognostic abilities were assessed via receiver operating characteristic (ROC) curves and Kaplan-Meier curves. Cell proliferation was assessed via the Cell Counting Kit-8 assay, migration via the wound healing assay, and invasion via Transwell experiments. The molecular mechanisms underlying MRPL42 knockdown-mediated suppression of HCC progression were analyzed via transcriptome sequencing. Western blot analysis was used to measure protein levels. The ATP content and mitochondrial respiratory chain complex I activity were determined via commercial reagent kits.
resultsMRPL42 overexpression predicted HCC occurrence and poor prognosis. MRPL42 knockdown suppressed the malignant functions of HCC. Transcriptomic analysis revealed that differentially expressed genes after MRPL42 knockdown were closely linked to oxidative phosphorylation (OXPHOS). MRPL42 knockdown inhibited the protein expression of the mitochondrial activity markers PGC-1α and MT-ND1 and reduced ATP content and mitochondrial respiratory chain complex I activity, indicating that MRPL42 deficiency impaired mitochondrial OXPHOS. Furthermore, MRPL42 knockdown suppressed the malignant functions of HCC cells by regulating OXPHOS.
conclusionMRPL42 is overexpressed in HCC and is a potential biomarker for HCC diagnosis and prognosis. In regulating OXPHOS, MRPL42 knockdown suppressed HCC malignant function, highlighting its potential as a therapeutic target.
Indexed as
Identifiers
41790391What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.